Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies
Articles
THERAPEUTIC FOCUS – Targeted Payload Therapies Radiate Potential to Attack Various Cancers January 8, 2015
Kaushik J. Dave, PhD, MBA, and Dragan Cicic, MD, MBA, indicate that alpha-particle emitters, such as bismuth-213 or actinium-225, may be more effective and efficient at killing cancerous cells not currently treated with radiation while simultaneously decreasing nonspecific cytotoxic effects.
GENETIC MODIFICATION THERAPIES – Clinical Applications & Technology Platforms November 12, 2018
Laurie L. Sullivan and John Bergin, MS, MBA, say the growing interest on the part of large pharma or biotech companies is driving clinical development of genetic modification therapy candidates, and the rich late-stage pipeline for genetic modification therapy candidates is a driving force of growth.
PLATFORM TECHNOLOGY – The 3DNA® Platform for Targeted Drug Delivery November 7, 2016
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
Madrigal Pharmaceuticals & Tarveda Therapeutics Announce Exclusive License Agreement September 25, 2016
Madrigal Pharmaceuticals, Inc. and Tarveda Therapeutics, Inc. recently announced an exclusive worldwide license agreement providing for the discovery, development, and...LIPID NANOPARTICLES – EnCore(TM): Facilitating Delivery of RNAi Therapeutics to Treat Cancer March 29, 2016
Marc T. Abrams, PhD, and Bob D. Brown, PhD, explain how nanoparticle technology has the potential to enable tumor bioavailability even in the absence of a targeting ligand.
MARKET BRIEF – Controlled Release Technologies: Advancing Toward Targeting Therapeutics June 10, 2013
Frost & Sullivan Analyst Cecilia Van Cauwenberghe, MS, reviews a few recent innovative approaches to controlled release technologies with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
SPECIAL FEATURE – Injection Devices: Designing Simplicity, Safety & Adherence Into One Delivery System August 26, 2021
Contributor Cindy Dubin, in this annual report, speaks with industry innovators and takes a deep dive into the myriad injectables that are currently in development or recently introduced to the market.
GENE THERAPY – Solving the Puzzle: Aligning the Pieces of Gene Therapy & Creating Success for Patients August 26, 2021
Sue Washer, MBA, reviews the various elements that must come together in developing safe, effective, and commercially viable viral-based gene therapies.
PLATFORM TECHNOLOGY – Overcoming the Challenges of Drug Brain Delivery With a Novel Brain Delivery Vector November 23, 2020
Mei Mei Tian, PhD, explains how the xB3 platform has the potential to support development of treatments for CNS diseases that can treat thousands of patients in the years ahead.
NEXT-GENERATION TUMOR TARGETING – Leveraging the Tumor Microenvironment to Change the Standard of Care June 4, 2020
Vishwas Paralkar, PhD, highlights a unique platform technology that represents the first technology that has successfully been used to target cancer drugs to tumor cells in animal models, while sparing healthy tissue.
Triphase Accelerator & Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial May 19, 2020
Triphase Accelerator and Catalent recently announced interim results for Triphase Accelerator's multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated...SPECIAL FEATURE – Injection Devices: Wearables, Connectivity & Patient-Centric Designs Empower Self-Administration September 3, 2019
Contributor Cindy H. Dubin highlights the innovation in injection devices – from wearables to connectivity to varied dose administration – that have occurred in the past year.
SPECIAL FEATURE – Prefilled Syringes & Parenteral Manufacturing: Flexibility for Faster Development April 30, 2019
Contributor Cindy H. Dubin interviews several contract manufacturers and device developers who are responsible for creating next-generation parenteral drug delivery.
BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration April 9, 2019
BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).
NANOPARTICLE DELIVERY – Ultra-Small Particles Offer Big Hope in Cancer Theranostics February 28, 2019
Kai Ma, PhD, Ulrich Wiesner, and Michelle Bradbury, MD, PhD, believe ultra-small sub-10 nm particles hold unique properties and represent an emerging area of investigation for biomedical applications.
ANTIBODY DRUG CONJUGATES – Expansion of Approved Indications Backs 25% Increase in Global Market October 1, 2018
Laurie L. Sullivan and Shalini Shahani Dewan, MS, believe technological advancements, the rising incidence of cancer, and an increasing demand for biologic therapies are all factors driving growth in the global ADC market.
Telix Completes Acquisition of Atlab for Prostate Cancer Program September 13, 2018
Telix Pharmaceuticals Limited recently announced completion of the acquisition of Atlab Pharma SAS. The option to acquire Atlab for the...INJECTABLE NANOMEDICINES – New Developments in Long-Acting Injectable Nanoformulations May 22, 2018
Dongwei Guo, PhD, and Jingjun Huang, PhD, focus on the overview of nanoproducts in the market and the technologies to make long-acting injectable nanoformulations.
SPECIAL FEATURE – Formulation Development & Manufacturing – CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
SPECIAL FEATURE – Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
